Trastuzumab mechanism of action; 20 years of research to unravel a dilemma

H Maadi, MH Soheilifar, WS Choi, A Moshtaghian… - Cancers, 2021 - mdpi.com
Simple Summary Overexpression of HER2 receptors have been identified in various types of
cancer including breast cancer and ovarian cancer. HER2 overexpression is generally …

Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives

C Vernieri, M Milano, M Brambilla, A Mennitto… - Critical reviews in …, 2019 - Elsevier
HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …

Virus-like particle display of HER2 induces potent anti-cancer responses

A Palladini, S Thrane, CM Janitzek, J Pihl… - …, 2018 - Taylor & Francis
Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20–30% of
invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven …

HER2 signaling and breast cancer stem cells: The bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness

SM Pupa, F Ligorio, V Cancila, A Franceschini… - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer (BC) is not a single disease, but a group of different tumors,
and altered HER2 expression defines a particularly aggressive subtype. Although HER2 …

HER2-displaying M13 bacteriophages induce therapeutic immunity against breast cancer

J Wang, A Lamolinara, L Conti, M Giangrossi, L Cui… - Cancers, 2022 - mdpi.com
Simple Summary The high incidence and death rates of breast cancer make the
development of new therapies an urgent need. The introduction into the clinic of the anti …

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression

V Giusti, F Ruzzi, L Landuzzi, ML Ianzano, R Laranga… - Oncogenesis, 2021 - nature.com
HER2-positive breast cancers may lose HER2 expression in recurrences and metastases. In
this work, we studied cell lines derived from two transgenic mammary tumors driven by …

[HTML][HTML] HER2 splice variants in breast cancer: Investigating their impact on diagnosis and treatment outcomes

V Hart, H Gautrey, J Kirby, A Tyson-Capper - Oncotarget, 2020 - ncbi.nlm.nih.gov
Overexpression of the HER2 receptor occurs in approximately 20% of breast cancer
patients. HER2 positivity is associated with poor prognosis and aggressive tumour …

SIRT6 promotes metastasis and relapse in HER2-positive breast cancer

C Andreani, C Bartolacci, G Persico, F Casciaro… - Scientific reports, 2023 - nature.com
The histone deacetylase sirtuin 6 (SIRT6) has been endowed with anti-cancer capabilities in
many tumor types. Here, we investigate the impact of SIRT6-overexpression (SIRT6-OE) in …

Targeting alternative splicing in cancer immunotherapy

N Han, Z Liu - Frontiers in Cell and Developmental Biology, 2023 - frontiersin.org
Tumor immunotherapy has made great progress in cancer treatment but still faces several
challenges, such as a limited number of targetable antigens and varying responses among …

[HTML][HTML] Abnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy

K Deng, J Yao, J Huang, Y Ding, J Zuo - Translational Oncology, 2021 - Elsevier
Abnormally alternative splicing events are common hallmark of diverse types of cancers.
Splicing variants with aberrant functions play an important role in cancer development. Most …